Recruiting Myalgic Encephalomyelitis Studies in Albuquerque
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mas...
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the ...
Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)
A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms exp...
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during ...
Ketamine for Methamphetamine Use Disorder
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week rando...
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex media...
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...
Uterine Preservation Via Lifestyle Transformation
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develo...
About Myalgic Encephalomyelitis Clinical Trials in Albuquerque
Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.
There are currently 8 myalgic encephalomyelitis clinical trials recruiting participants in Albuquerque, NEW%20MEXICO. These studies are seeking a combined 1,369 participants. Research is being sponsored by Angitia Biopharmaceuticals, NICHD Neonatal Research Network, Foundation for Advancing Veterans' Health Research and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myalgic Encephalomyelitis Clinical Trials in Albuquerque — FAQ
Are there myalgic encephalomyelitis clinical trials in Albuquerque?
Yes, there are 8 myalgic encephalomyelitis clinical trials currently recruiting in Albuquerque, NEW%20MEXICO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Albuquerque?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Albuquerque research site will contact you about next steps.
Are clinical trials in Albuquerque free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Albuquerque studies also compensate for your time and travel.
What myalgic encephalomyelitis treatments are being tested?
The 8 active trials in Albuquerque are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.
Data updated March 2, 2026 from ClinicalTrials.gov